In a systematic review of nicotine use disorder, semaglutide showed indirect behavioral benefits in real-world observational data.
In plain wordsA review found that semaglutide showed indirect behavioral benefits for smoking in real-world observational data.
- Peptide
- Semaglutide
- Outcome
- Direction not reportedIndirect behavioral benefits for smoking cessation in real-world observational data
- Study
n: not reported in source
- Outcome group
- Addiction, withdrawal and alcohol intake · Mental health and mood
- Studied dose
- Dose not stated
Source sentences
Semaglutide showed indirect behavioral benefits in real-world observational data.
1 context sentence(design, population, supporting numbers)
Eligible studies included randomized controlled trials (RCTs), observational cohorts, and preclinical rodent studies evaluating GLP-1 or GLP-1/GIP agonists in nicotine-related outcomes.